Daniel Domjan, MD
General Practice · Sikeston, MONPI 1235119215
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 412 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 412 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$843
- AstraZeneca$805
- Boehringer Ingelheim$628
- Novo Nordisk$509
- Amgen$437
- Bayer$436
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,44797%
- Education$1803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 52 | $843 |
| AstraZeneca | 33 | $805 |
| Boehringer Ingelheim | 37 | $628 |
| Novo Nordisk | 34 | $509 |
| Amgen | 34 | $437 |
| Bayer | 23 | $436 |
| AbbVie(2 entities) | 24 | $414 |
| Amarin Pharma, Inc. | 26 | $356 |
| Merck | 17 | $257 |
| Pfizer | 32 | $242 |
| Astellas Pharma US Inc | 10 | $241 |
| Ironwood Pharmaceuticals, Inc | 14 | $205 |
| Kowa Pharmaceuticals America, Inc. | 11 | $164 |
| Novartis | 8 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $94 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $83 |
| Eisai Inc. | 5 | $74 |
| Exact Sciences | 3 | $61 |
| Dexcom, Inc. | 3 | $52 |
| Johnson & Johnson | 2 | $51 |
| Grifols USA, LLC | 3 | $48 |
| Mylan Specialty L.p. | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Abbott | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 3 | $37 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Medicure Pharma Inc. | 1 | $13 |
| GSK | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,627 in reported general payments places this provider in the 95th percentile of 1,446 general practice providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 110 | $134,441 |
| Repatha SureclickEvolocumab | 114 | $103,787 |
| TrulicityDulaglutide | 72 | $98,138 |
| JardianceEmpagliflozin | 66 | $98,038 |
| LinzessLinaclotide | 99 | $90,760 |
| TradjentaLinagliptin | 64 | $71,608 |
| MounjaroTirzepatide | 56 | $71,571 |
| EliquisApixaban | 65 | $59,082 |
| FarxigaDapagliflozin Propanediol | 58 | $47,229 |
| VascepaIcosapent Ethyl | 93 | $44,435 |
| LivaloPitavastatin Calcium | 57 | $32,859 |
| MyrbetriqMirabegron | 37 | $32,419 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 101 | $31,533 |
| Praluent PenAlirocumab | 36 | $30,350 |
| XareltoRivaroxaban | 32 | $25,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $843 | $169,709128 claims |
| Boehringer IngelheimJardiance, Tradjenta | $628 | $169,646130 claims |
| Novo NordiskOzempic | $509 | $134,441110 claims |
| AbbVieLinzess | $414 | $90,76099 claims |
| PfizerEliquis, Abrysvo | $242 | $90,614166 claims |
| AstraZenecaFarxiga, Symbicort | $805 | $65,424103 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $164 | $32,85957 claims |
| Astellas Pharma US IncMyrbetriq | $241 | $32,41937 claims |
| Johnson & JohnsonXarelto | $51 | $25,56632 claims |
| MerckBelsomra | $257 | $23,39453 claims |
| BayerKerendia | $436 | $21,95914 claims |
| GSKShingrix | $12 | $21,50499 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,446 general practice providers in Missouri.
Other general practice in Sikeston
- Baron GrutterGladstone$445K
- Arthur GreenbergKansas City$241K
- Robert CalaluceColumbia$189K
- Suraiya SiddiqueMount Vernon$61K
- John FluckeLees Summit$60K
- Rex HudsonSaint Louis$49K
- David KaelinCape Girardeau$27K
- Nadeemuddin QureshiSaint Louis$22K
- Michael McKenzieHannibal$20K
- Robert McGrawCameron$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.